Last reviewed · How we verify

Stelara — Competitive Intelligence Brief

Stelara (ustekinumab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed p40 protein subunit of IL-12 and IL-23 Immunology Live · refreshed every 30 min

Target snapshot

Stelara (ustekinumab) — Johnson & Johnson. Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Stelara TARGET ustekinumab Johnson & Johnson marketed p40 protein subunit of IL-12 and IL-23
STEQEYMA USTEKINUMAB-STBA CELLTRION, INC. marketed Interleukin-12 Antagonist [EPC] p40 protein subunit of IL-12 and IL-23

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Stelara — Competitive Intelligence Brief. https://druglandscape.com/ci/ustekinumab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: